Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: The frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few studies have evaluated the treatment outcome of MAC pulmonary disease in Korea. Methods: The efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42 patients treated for more than 6 months between January 2005 and December 2008. All patients were treated with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients. Results: Among the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months; IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs.54.5%, p = 0.038). Conclusions: The combined regimen including clarithromycin was effective against MAC pulmonary disease. High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary disease.
Abstract
Background/Aims: The frequency of nontuberculous mycobacteria pulmonary disease in HIV-negative patients is increasing; the most common pathogen in Korea is the Mycobacterium avium complex (MAC). However, few studies have evaluated the treatment outcome of MAC pulmonary disease in Korea. Methods: The efficacy of a clarithromycin-containing regimen for MAC pulmonary disease was studied in 42 patients treated for more than 6 months between January 2005 and December 2008. All patients were treated with a regimen consisting of clarithromycin, rifampin, and ethambutol. Streptomycin was added in 10 patients. Results: Among the 42 patients, a negative culture conversion was achieved in 33 (78.6%), and the median duration of treatment in these patients was 19 months (interquartile range [IQR], 16 to 22). Of the 33 patients with a negative culture conversion, 14 completed treatment. During the follow-up period (median, 10 months; IQR, 4 to 20) for the 14 patients, one relapsed at 24 months after treatment completion. The culture conversion rate was significantly higher in patients who were treated with more than 500 mg/day clarithromycin (87.1% vs.54.5%, p = 0.038). Conclusions: The combined regimen including clarithromycin was effective against MAC pulmonary disease. High-dose clarithromycin of more than 500 mg/day may improve the outcome of patients with MAC pulmonary disease.
참고문헌 (22)
- Koh WJ, "Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea", Chest, 129, pp.341~348 (2006)
- 이정연, "한 대학병원에서 비결핵항산균의 분리 및 동정실태", Tuberculosis and Respiratory Diseases, 58(4), pp.385~391 (2005), 대한결핵및호흡기학회
- 최순필, "일개 국립결핵병원에서 경험한 비결핵성 마이코박테리아 폐질환의 원인균과 임상상", Tuberculosis and Respiratory Diseases, 59(6), pp.606~612 (2005), 대한결핵및호흡기학회
- Koh WJ, "Diagnosis and treatment of nontuberculous mycobacterial lung disease", Korean J Med, 74, pp.120~131 (2008)
- 전경만, "비결핵 항산균 폐질환의 진단에서 기관지내시경술의 유용성", Tuberculosis and Respiratory Diseases, 57(3), pp.242~249 (2004), 대한결핵및호흡기학회
- Griffith DE, "An official ATS", IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases, 2007, pp.175, 367~416
- Korean Academy of Tuberculosis and Respiratory Disease, "Guidelines for the management of tuberculosis" (2005), Korean Academy of Tuberculosis and Respiratory Disease
- 고원중, "Mycobacterium avium Complex (MAC) 폐질환의 치료성적", Tuberculosis and Respiratory Diseases, 57(3), pp.234~241 (2004), 대한결핵및호흡기학회
- "Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999", Am J Respir Crit Care Med, 161(4), pp.1379~1395 (2000)
- Kee SJ, "Multiplex PCR assay for identification of mycobacterial species isolated from liquid cultures", Chonnam Med J, 45, pp.19~26 (2009)
- Dautzenberg B, "Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS: Clarithromycin Study Group of France", Chest, 107, pp.1035~1040 (1995)
- Wallace RJ Jr, "Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients", Am J Respir Crit Care Med, 153, pp.1766~1772 (1996)
- Field SK, "Mycobacterium avium complex pulmonary disease in patients without HIV infection", Chest, 126, pp.566~581 (2004)
- Wallace RJ Jr, "Drug intolerance to highdose clarithromycin among elderly patients", Diagn Microbiol Infect Dis, 16, pp.215~221 (1993)
- Carter G, "A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation", Antimicrob Agents Chemother, 48, pp.4907~4910 (2004)
- Hasegawa N, "Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease", Pulm Pharmacol Ther, 22, pp.190~193 (2009)
- Kobashi Y, "The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study", Respiration, 74, pp.394~400 (2007)
- Hasegawa N, "Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease", Chest, 136, pp.1569~1575 (2009)
- Fujikane T, "Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease", Int J Tuberc Lung Dis, 9, pp.1281~1287 (2005)
- Tanaka E, "Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease", Am J Respir Crit Care Med, 160, pp.866~872 (1999)
- Lam PK, "Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease", Am J Respir Crit Care Med, 173, pp.1283~1289 (2006)
- "Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association", Am J Respir Crit Care Med, 156(2), pp.1~25 (1997)